NCT03970096
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 32 versions: 25 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 31, 2027 to Dec 31, 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 14 words
- Study completion pushed from Dec 31, 2029 to Dec 31, 2030
- Secondary endpoints: details revised at 3 of 5 entries
- Site details revised at 1 of 3 sites
- Notable Primary completion date: Dec 31, 2026 to Dec 31, 2027
- Study completion date: Dec 31, 2028 to Dec 31, 2029
- Notable Eligibility criteria expanded, about 6 wordsv27
- Notable Eligibility criteria revisedv26
- Notable Eligibility criteria expanded, about 16 words
- Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Busulfan (Drug), Cyclophosphamide (Drug), Cyclosporine (Drug)… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Biospecimen Collection (Procedure), Bone Marrow Aspiration and Biopsy…
- Study description expanded, about 32 words
Show 19 earlier versionsHide 19 earlier versions
- Notable Primary completion date: Aug 1, 2025 to Dec 31, 2026
- Study completion date: Aug 1, 2026 to Dec 31, 2028
- Minor Study description expanded, about 24 wordsv23
- Notable Eligibility criteria shortened, about 27 words
- Site details revised at 1 of 3 sites
- Notable Eligibility criteria expanded, about 7 wordsv21
- Notable Primary completion date: Aug 1, 2023 to Aug 1, 2025
- Study completion date: Aug 1, 2024 to Aug 1, 2026
- Minor Study description expanded, about 182 words
- Study arms: 4 to 6
- Notable Eligibility criteria expanded, about 73 words
- Study description shortened, about 184 words
- Study arms: 6 to 4
- Study title expanded, about 4 words
- Notable Eligibility criteria expanded, about 16 words
- Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Cyclophosphamide (Drug), Cyclosporine (Drug), Fludarabine (Drug)… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Busulfan (Drug), Cyclophosphamide (Drug), Cyclosporine (Drug)…
- Study description expanded, about 313 words
- Study arms: 3 to 6
Notable Eligibility criteria expanded, about 16 wordsv14 Show 5 more changesShow less
- Enrollment target: 160 to 120
- Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Cyclophosphamide (Drug), Cyclosporine (Drug), Fludarabine (Drug)…
- Secondary endpoints revised (5)
- Study description shortened, about 52 words
- Study arms: 4 to 3
- Notable Eligibility criteria expanded, about 19 wordsv13
- Minor Site details revised at 1 of 3 sitesv12
- Notable Eligibility criteria expanded, about 2 words
- Study description revised
- Minor Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells…
- Secondary endpoints: details revised at 1 of 5 entries
- Study description expanded, about 27 words
- Notable Eligibility criteria revised
- Study sites: 2 to 3
- Interventions: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells… to Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Biological), Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells…
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Nov 15, 2019 to Nov 19, 2019
- Site details revised at 2 of 2 sites
- Notable Start date: Oct 15, 2019 to Nov 15, 2019v5
- Minor Start date: Sep 19, 2019 to Oct 15, 2019v4
- Notable Start date: Aug 8, 2019 to Sep 19, 2019v3
- Notable Start date: Jul 6, 2019 to Aug 8, 2019v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients undergo TBI BID on days -10 to -7, and receive thiotepa IV over 3 hours on days -6 and -5, fludarabine IV over 30 to 60 minutes on days -6 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Patients receive fludarabine IV over 30 to 60 minutes on days -6 to -2, busulfan IV over 180 minutes on days -5 to -2, and undergo TBI BID on day -1. Patients also receive tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, CD34+ enriched CD45RA-depleted donor T-lymphocytes IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Patients undergo TBI BID on days -4 to -2 or -3 to -1, and receive PBSC IV on day 0. Patients also receive cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Patients receive fludarabine IV over 30 to 60 minutes on days -5 to -2, busulfan IV over 180 minutes on days -5 to -2, PBSC IV on day 0, cyclophosphamide IV over 1 to 2 hours on days 3 and 4, and tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day 5. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Patients undergo TBI BID on days -6 to -4, and receive cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Patients receive busulfan IV over 180 minutes on days -8 to -5, cyclophosphamide IV over 1 hour on days -3 to -2, tacrolimus (or cyclosporine or sirolimus if toxicities occur) IV continuously starting on day -1, PBSC IV on day 0, and methotrexate IV on days 1, 3, 6, and 11. If there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus (or cyclosporine or sirolimus) is tapered per month for capsules (or per week for liquid). Patients also undergo bone marrow aspiration/biopsy, ECHO or MUGA scan, and collection of blood samples throughout the trial.
Radiation: Total-Body Irradiation
Drugs: Thiotepa, Fludarabine, Tacrolimus, Methotrexate, Cyclophosphamide, Cyclosporine, Sirolimus, Busulfan
Biologicals: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Peripheral Blood Stem Cell
Procedures: Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection
Sites
3 sites in 1 country